BOTHELL, WA--(Marketwire - December 13, 2010) - Marina Biotech, Inc. (
Parties interested in participating in the live conference call can contact Melissa Woodson, Rodman & Renshaw, at 212.430.1782 for specific details and availability. Institutional investors are invited to access the video replay of the presentation at the RodmanTV website: http://www.rodm.TV.
About Marina Biotech, Inc.
Marina Biotech is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.
Contact Information:
Contact:
Marina Biotech, Inc.:
Pete Garcia
Chief Financial Officer
(425) 908-3603